Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics
Autore:
Garcia, PS; Paty, I; Leister, CA; Guerra, P; Frias, J; Perez, LEG; Darwish, M;
Indirizzi:
Autonomous Univ Madrid, Dept Pharmacol & Therapeut, E-28049 Madrid, Spain Autonomous Univ Madrid Madrid Spain E-28049 apeut, E-28049 Madrid, Spain Hosp La Paz, Clin Pharmacol Unit, La Paz, Bolivia Hosp La Paz La Paz Bolivia La Paz, Clin Pharmacol Unit, La Paz, Bolivia Wyeth Ayerst Res, Paris, France Wyeth Ayerst Res Paris FranceWyeth Ayerst Res, Paris, France Wyeth Ayerst Res, Radnor, PA USA Wyeth Ayerst Res Radnor PA USAWyeth Ayerst Res, Radnor, PA USA Hosp La Paz, Clin Pharmacol Serv, La Paz, Bolivia Hosp La Paz La Paz Bolivia La Paz, Clin Pharmacol Serv, La Paz, Bolivia
Titolo Testata:
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
fascicolo: 24, volume: 57, anno: 2000,
pagine: 2267 - 2270
SICI:
1079-2082(200012)57:24<2267:EOZODP>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
METABOLISM; BIOAVAILABILITY; PREVALENCE; TOXICITY;
Keywords:
anxiolytics, sedatives, and hypnotics; blood levels; cardiac drugs; digoxin; drug interactions; pharmacodynamics; pharmacokinetics; toxicity; zaleplon;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Garcia, PS Autonomous Univ Madrid, Dept Pharmacol & Therapeut, Ave Arzobispo Morcillo,S-N, E-28049 Madrid, Spain Autonomous Univ Madrid Ave ArzobispoMorcillo,S-N Madrid Spain E-28049
Citazione:
P.S. Garcia et al., "Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics", AM J HEAL S, 57(24), 2000, pp. 2267-2270

Abstract

The pharmacokinetics and pharmacodynamics of digoxin alone and digoxin plus zaleplon were studied. Healthy, nonsmoking men between 18 and 45 years of age were given a singleoral dose of digoxin 0.375 mg daily on days 1 through 9. On days 10 through 14, the subjects received digoxin 0.375 mg plus oral zaleplon 10 mg daily. Blood samples were obtained on days 3, 5, 8, 9, and 14 and se-rum digoxinconcentration data were analyzed by model-independent pharmacokinetic methods. Blood pressure, heart rate, PR interval, and QTc interval were recorded to determine the effect of zaleplon on digoxin pharmacodynamics. A total of 20 men completed the study. Maximum serum digoxin concentrationand area under the serum digoxin concentration-versus-time curve from. 0 to 24 hours met bioequivalence test criteria. There were no significant differences in QTc or PR interval between days 9 (digoxin alone) and 14 (digoxin plus zaleplon), and there were no clinically important changes from baseline to the study's end in vital signs, physical examination findings, or ECG results for individual subjects. Eighteen percent of the subjects who received digoxin alone and 35% of those who received digoxin plus zaleplon reported one or more adverse effects; all were mild and resolved quickly. Zaleplon had no significant effects on selected pharmacokinetic and pharmacodynamic properties of digoxin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 13:07:52